MedX Health Corp Reports Financial Results 2nd Quarter 2010

MedX Health Corporation Issues Shares for Debt

Sets Annual and Special Meeting of Shareholders Date

MISSISSAUGA, ON, Aug. 30 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced revenue for the quarter ended June 30, 2010 was $79,427, a 25.5% per cent decrease from the quarter ended June 30, 2009. MedX incurred a loss for the quarter of $279,390 or $0.01 per share compared to a loss of $538,971 or $0.02 per share for the same period in the prior year.  Revenue for the first 6 months of 2010 was $245,466, a 46.4 per cent decrease over the same period in 2009.

"We are continuing to rebuild our distribution base. The addition of the RJ Laser products are beginning to improve our revenues which will allow us to continue to expand our marketing initiatives, and we are seeking funding to accelerate this process, says Steve Guillen, president & CEO.  "Additionally, we recently announced a Letter of Intent (LOI) with Medical Marketing Berlin GmbH (MMB) for the exclusive North American marketing rights to the H'andy sana 211, a touch screen cell phone with an integrated ECG, a drug reminder and a 'Health Suite' in which blood glucose, cholesterol and blood pressure can be managed, and this will accelerate our revenue growth and improve our access to capital over the coming year," said Mr. Guillen.

MedX Issues Shares for Debt

MedX has also issued 5,668,307 million shares in settlement of $566,830.70 in obligations to several parties.  These shares are subject to a hold period expiring December 17, 2010. The number of fully diluted MedX Health Corp. shares outstanding is now 34,219,834 million.

MedX Shareholders Meeting Date

MedX further announced that the Annual and Special Meeting of Shareholders will be on Thursday, September 30, 2010, at 4 p.m. at The National Club, located at 303 Bay Street, Toronto, Ontario.

About MedX Health Corp.

MedX is a leading North American developer and manufacturer of low level laser and light medical devices for the drug free and non-invasive treatment of tissue damage and pain in numerous medical settings including dental, rehabilitation and wound care. MedX is the world's only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for, the bringing of non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments.

MedX's strategy is to build upon its success in bringing relief of conditions in a non-pharmacologic manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as well as developing and commercializing advanced products in the dental and wound-care markets that will position the company to increase revenue. In addition, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its "Photobandage™", a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development of marketing and sales.

Brand products are US FDA approved, Health Canada cleared, and CE Marked and are produced in an ISO 9001 and 13485 certified manufacturing and testing facility. For a complete profile of MedX Health Corp. and its products visit www.medXhealth.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.


%SEDAR: 00017466E

SOURCE MedX Health Corp.

For further information: For further information:

Investors:

Steve Guillen
President and Chief Executive Officer
MedX Health Corp.
Phone: (905) 670-4428
info@medxhealth.com

Organization Profile

MedX Health Corp.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890